anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This group will perform overall stability and body balancing exercises to strengthen the core and develop the coordination and balance required for task performance. Each activity will be performed in a set of 2-3, considering the activity level of the child, with 8-12 repetitions attaining the available ROM and flexibility of the child thrice for three weeks. The participants will undergo warm-up before the exercise and cool-down afterwards.
The application of a robotic platform in the bariatric surgical field is intended to enhance the already established advantages of minimally invasive surgery in terms of both technical and clinical outcomes. These advantages are especially relevant for technically challenging multiquadrant operations such as Roux-en-Y Gastric Bypass (RYGB). Consequently, robotic-assisted surgery has emerged as a possible application for bariatric surgeries. The study attempts to assess feasibility and safety of the Hugo™-Robotic-Assisted Surgery System (Hugo™-RAS) platform compared to the DaVinci® Surgical System (DaVinci®-SS) with a focus on complication rates and operative times. We retrospectively reviewed bariatric procedures performed from January 2013 until December 2023. We included all robotic RYGBs performed using Hugo™-RAS and DaVinci®-SS platforms. The study utilized Propensity Score Matching (PSM) analysis to address bias in selection, matching patients based on age, gender, body mass index, comorbidities and past abdominal operations. One hundred thirty-five patients were identified: 90 DaVinci®-SS and 45 Hugo™-RAS procedures. After PSM, each group consisted of 45 patients. There was no discernible disparity observed in relation to early (≤ 30 days) postoperative complications rate (p = 1), mean operative time (for docking time, console time and total operative time: p = 0.176, p = 0.678, p = 0.229, respectively) and postoperative hospital stay (p = 0.052) between DaVinci®-RSS and Hugo™-RAS procedures. Our results suggest that application of both Hugo™-RAS and DaVinci®-SS robotic platforms to RYGB is related to comparable safety profiles. Although DaVinci®-SS remains the most widely adopted platform in clinical practice, this study underscores the potential role of the Hugo™-RAS to provide effective solutions in robotic bariatric procedures.
Aortic aneurysms (AA) and aorta dissection (AD) are life-threatening conditions with a rising incidence and high mortality rate. Recent research has linked non-coding RNAs to the regulation of AA and AD progression. In this study, we performed circRNA sequencing, microRNA (miRNA) sequencing, and messenger RNA (mRNA) sequencing on plasma samples from AA and AD patients to identify the key circRNA-miRNA-mRNA axis involved in the transition from AA to AD. Our results showed elevated levels of circ_0000006 and circ_0000160, along with decreased levels of hsa-let-7e-5p in AD samples compared to AA samples. Predictive analysis suggested that circ_0000006 and circ_0000160 potentially target hsa-let-7e-5p, which in turn may bind to the mRNA of Ubiquilin 4 (UBQLN4). In an AD cell model using vascular smooth muscle cells (VSMCs), silencing circ_0000006 and circ_0000160 attenuated the effects of platelet-derived growth factor (PDGF)-induced phenotypic changes, proliferation, and migration. This effect was partially reversed by inhibiting hsa-let-7e-5p. Furthermore, we found that overexpression of UBQLN4 counteracted the effects of hsa-let-7e-5p, suggesting UBQLN4 as a downstream mediator of hsa-let-7e-5p. In an animal model of AD, knockdown of circ_0000006 and circ_0000160 also showed protective effects against aortic septation. Overall, our findings indicate that the upregulation of circ_0000006 and circ_0000160 contributes to the progression from AA to AD by influencing abnormal phenotypic changes, migration, and proliferation of VSMCs. The Hsa-let-7e-5p/UBQLN4 axis may play a critical role in AD development. Targeting circ_0000006 and circ_0000160 could be a potential therapeutic strategy for preventing the progression of AD.
BACKGROUND: Failure to rescue, or the death of a patient after a surgical complication, largely occurs in patients who develop a cascade of postoperative complications. However, it is unclear whether there are specific types of index complications that are more strongly associated with failure to rescue, additional secondary complications, or other types of postoperative outcomes. This is a national cohort study of veterans who underwent noncardiac surgery at Veterans Affairs hospitals using data from the Veterans Affairs Surgical Quality Improvement Program (January 1, 2016 to September 30, 2021). Index complications were grouped into categories (cardiovascular, venous thromboembolism, pulmonary, bleeding/transfusion, renal, central nervous system, wound, sepsis, Clostridium difficile colitis, graft, or minor [defined as complications having an associated mortality rate <1%]). The association between type of index complication and failure to rescue, secondary complications, reoperation, and postoperative length of stay was evaluated with multivariable, hierarchical regression, and risk of death assessed with shared frailty modeling.
RESULTS: Among 574,195 patients, 5.3% had at least 1 complication (of which 26.1% had secondary complications, and 8.2% had failure to rescue), and 4.5% had a reoperation. Secondary complication (5.0%-61.4%) and failure to rescue (0.8%-34.2%) rates varied by the type of index complication. Relative to index minor complications, index bleeding was most associated with secondary complication (subdistribution hazard ratio 1.4, 95% confidence interval [1.1-1.8]), index cardiac complications were most associated with failure to rescue (odds ratio 45.4 [34.5-59.7]), index graft complications were most associated with reoperation (odds ratio 96.0 [79.5-115.8]), and index pulmonary complications were associated with 2.6 times longer length of stay (incident rate ratio 2.6 [2.6-2.7]). Index cardiac and central nervous system complications were most strongly associated with risk of death (cardiac-hazard ratio 2.45, 95% confidence interval [2.14-2.81]; central nervous system-hazard ratio 1.84 [1.49-2.27]).
CONCLUSION: Different types of index complications are associated with different outcome profiles. This suggests surgical quality improvement efforts should be tailored not only to the type of index complication to be addressed but also to the desired outcome to improve.
Cosmetic compsn. for applying to nails includes a film-forming agent comprising an aq. dispersion of particles of polyurethane (PU) of Tg at up to 30 degrees C and radical polymers with carboxylic gp.. When the Tg of the PU is more than 0 degrees C, the radical polymer(s) has a min. film-forming temp. (FFT) of up to 30 degrees C and/or is present at 5-60% and when the Tg of the PU is below 0 degrees C, the radical polymer(s) is present at 5-70%.
A controlled release oral formulation for use with a variety of drugs, e.g. anti-Parkinsonian, cardiovascular and anti-epileptic drugs are formed in liquid suspension form. The ingredients in the suspension are water, an edible oil and a stabilizer for the liquid suspension, at least one pharmaceutically active ingredient, at least two water soluble biodegradable polymers, and optionally with at least one antioxidant to prevent degradation and oxidation of the pharmaceutically active ingredients. Suitable polymers are polysucrose, copolymer of sucrose and epichlorohydrin, hydroxyethyl cellulose hydroxypropyl-ethyl cellulose, hydoxypropyl-methyl cellulose, gelatine, starch, modified crosslinked starch, polyethyleneimine, methoxypolyethylene glycol, polyethylene oxide, cellulose acetate, polyvinyl alcohol, sodium alginate, N,N-diethylaminoacetate, block copolymers of polyoxyethylene, block copolymers of polyoxypropylene, a mixture of hydroxyethyl cellulose and sodium carboxymethyl cellulose, and combinations thereof. Suitable edible oils are mineral oil, soyabean oil, coconut oil, vegetable oil and sunflower oil and combinations thereof. Suitable stabilizers are oleic acid, cholic acid, deoxycholic acid, pharmaceutically acceptable salts thereof and combinations thereof.      Suitable antioxidants are tocopherol, deteroxime mesylate, methyl paraben and ascorbic acid.      A typical teaspoon dose of anti-Parkinson liquid suspension contains 15-150 mg carbidopa, 50-1500 mg levodopa, 100-300 mg of a combination of polyvinyl alcohol and polysucrose, 10-50 mg oil, 5-15 mg antioxidant, e.g. vitamin E, 5-20 mg stabilizer, 10-15 mg colorants, 10-15 mg natural flavouring agents and 5 ml water.
PURPOSE:To obtain the titled cosmetic having small temperature dependence of hardness, easily removable in use and having high spreadability and low stickiness, by dispersing and emulsifying an organic perfluoro compound in a solution produced by dissolving a specific fluorine-containing surfactant in an oil component. CONSTITUTION:A fluorine-containing surfactant having perfluorocarbon group and hydrocarbon group in the molecule (e.g. perfluoropropylheptane) is dissolved in an oil component such as oil or fat, wax, hydrocarbon, esterified oil, higher alcohol, higher fatty acid, etc. An organic perfluoro compound (e.g. perfluorodecalin) is dispersed and emulsified in the above solution to obtain the objective non-aqueous emulsion-type hair-dressing cosmetic containing the organic perfluoro compound dispersed in an oil. EFFECT:It has excellent storage stability.
The invention provides a traditional Chinese medicine patch for treating juvenile bronchial asthma. The patch is prepared from the following raw medicinal materials in parts by weight: 1-3 parts of semen brassicae, 1-3 parts of asarum, 1-2 parts of cinnamon, 1-2 parts of ephedra and 1-3 parts of semen lepidii. The preparation method of the traditional Chinese medicine patch comprises the following steps: grinding the raw medicinal materials by using a traditional Chinese medicine grinding machine, screening through a 100-120 meshes screen, adding 90-100 DEG C water the addition of which is 0.7-0.8 time the amount of undersized material to the undersized material, and mixing to prepare drug cakes; cooling to a temperature below 50 DEG C so as to obtain the traditional Chinese medicine patch for treating juvenile bronchial asthma. According to the traditional Chinese medicine patch, ephedra and cinnamon are capable of opening lung and dispelling cold, asarum is capable of warming lung and dissolving dampness, semen brassicae is capable of promoting qi circulation and removing phlegm, semen lepidii is capable of promoting diuresis and dissolving dampness, and all the materials work together to play roles in warming lung, dissipating coldness, eliminating phlegm and relieving asthma. The traditional Chinese medicine patch penetrates to the subcutaneous area via the shu-acupoint so as to take the effect of the medicinal materials. The traditional Chinese medicine patch is mainly used for treating bronchial asthma with syndromes of cough asthma, throat wheezing, excessive phlegm with foam, cold body and limbs, thin nasal discharge, pale white complexion, aversion to cold without sweat, pale red tongue, white slip moss and superficial and rapid pulse.
BACKGROUND: Transverse myelitis (TM) is a demyelinating inflammatory disease that presents with motor, sensory, and autonomic dysfunction, which may be acute or subacute. COVID-19-associated TM has been described in a scarce number of patients.
CLINICAL CASE: A 15-year-old previously healthy male patient with respiratory disease before his neurological deterioration presented to the emergency room after developing a complete medullary syndrome located at the cervical-dorsal level, with ascending and symmetric paraparesis that rapidly progressed to paraplegia, with sensory dysfunction from the T3 level, sphincter dysfunction and sudden ventilatory deterioration that required mechanical ventilation. Magnetic resonance imaging was compatible with acute TM. Inflammatory and non-inflammatory etiologies were discarded. In addition, a positive severe acute respiratory syndrome coronavirus 2 test was obtained. Treatment included steroid pulses and plasmapheresis, with an insidious evolution.
CONCLUSION: COVID-19 is an infrequent cause of TM and should be suspected when other etiologies have been ruled out.
This disclosure relates in general to a stem cell treatment. This disclosure further relates to a stem cell treatment using a composition comprising stem cells having highly expressed Fas-L. This disclosure further relates to a stem cell treatment of multiple myeloma. This disclosure also relates to a composition comprising stem cells having highly expressed Fas-L. This disclosure also relates to preparation of a composition comprising stem cell having highly expressed Fas-L. This disclosure also relates to preparation of a composition comprising stem cells having highly expressed Fas-L by using a salicylate. An example of salicylate may be aspirin. This disclosure further relates to a stem cell treatment of multiple myeloma. This disclosure also relates to a stem cell treatment of an inflammatory disease and/or autoimmune disease.
Polyglycols and their ethers are used as liquefying agents in the production of preparations of stable sterilizable substances such as are suitable for injection and comprising barbituric acid derivatives, vitamins or hormones, trihalogenated ethyl alcohols and their urethanes, therapeutically active glucosides, and alkaloid or synthetic alkaloid-like substances.  Glycol monohydroxy-, di-hydroxy-, methoxy-, and ethoxy-ethyl-ethers are mentioned in examples as instances of suitable polyglycols or their ethers.  The utility of the said polyglycols depends in part on their suitability for injection but they may be used in the manufacture of preparations of the substances referred to for peroral administration. Specification 377,835, [Group XIII], is referred to.  The Specification as open to inspection under Sect. 91 also comprises the use of hydroxyalkyl and alkoxyalkyl ethers of polyhydric alcohols containing three carbon atoms e.g. glycerol mono-dihydroxypropyl ether, as liquefying agents and specifies as substances which may be liquefied terpene-like substances such as camphor, benzene derivatives, e.g. phenols and hydroxybenzoic acid esters, and digitoxin.  The Specification also refers to the use of the said liquefying agents in disinfectant and cosmetic preparations.  This subject-matter does not appear in the Specification as accepted.
Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.
BACKGROUND: Mesenchymal stromal cell (MSC) therapy commonly involves systemic infusion of MSCs, which undergo apoptosis in the lung and induce immunoregulatory macrophages that reduce disease. The relevance of this mode of action, however, is yet to be determined for MSCs administered via other routes. Here, we administered MSCs via subcutaneous (SC) injection into inflamed tissue and investigated the immunomodulatory effects on the local lymph node (LN), which is a major site for the initiation and regulation of immune responses.
METHODS: A mouse model of localised skin inflammation was established with low-dose lipopolysaccharide (LPS) to in vivo prime adipose-derived MSCs delivered via SC injection. We then analysed the immunomodulatory changes in the LN draining the inflamed tissue, as well as the neutrophil TNF response to LPS re-exposure.
RESULTS: When administered directly into the inflamed skin tissue, SC MSC injection induced an expansion of IL-10-producing MerTK+ subcapsular sinus macrophages and T cell zone macrophages, as well as activated CD44+ regulatory T cells (Tregs), in the draining LN, which was not observed in the non-draining LN. SC injection of viable, but not apoptotic, MSCs dampened TNF production by inflammatory cells in the draining LN when re-exposed to the inflammatory stimulus. SC injection of MSCs remote to the site of inflammation also did not attenuate the LN response to subsequent inflammatory challenge.
CONCLUSIONS: MSCs delivered directly into inflamed skin activated immunoregulatory cells in the local LN and inhibited LN responsiveness to subsequent inflammatory challenge. The immunoregulatory effects of SC-injected MSCs in the LN require priming by inflammatory cytokines in the local milieu. Furthermore, SC-injected MSCs exert anti-inflammatory effects in the draining LN prior to their apoptosis, in contrast to intravenously delivered MSCs, where anti-inflammatory effects are linked to their apoptosis.
Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects 1 million people in the United States. PD causes a variety of disabling symptoms, which impact movement as well as cognition. Historically, we have relied on medications that increase dopamine levels to treat PD, although we are recognizing more and more that other chemicals in the brain are involved in PD as well.

Droxidopa (Northera) is an approved drug for the treatment of low blood pressure in PD. It is a norepinephrine precursor, which is converted in the body to the neurotransmitter norepinephrine. This is a chemical that the body normally makes that has a variety of important activities in the brain and peripheral nervous system. In PD, the cells that make norepinephrine die off as part of the disease process. Therefore, people with PD often have low levels of norepinephrine in their blood and in their spinal fluid. Norepinephrine is important for maintaining blood pressure, which may be one reason that some people with PD have problems with their blood pressure falling too low when they stand up. This can lead to symptoms such as dizziness, lightheadedness, feeling faint, or sometimes passing out.

Droxidopa has been approved by the FDA for the treatment of low blood pressure in Parkinson's disease. However, as norepinephrine is also important for a lot of processes that happen in the brain as well, we believe that this medication may be also helpful for some of the other symptoms of PD. In particular, norepinephrine plays a key role in brain networks that are important for attention, decision making, and controlling movements and actions. In order for norepinephrine to reach the brain, it must cross the blood-brain barrier. Therefore, in this study we will be giving droxidopa along with carbidopa, which stops your body from breaking down norepinephrine in the blood stream and allows it to get into the brain. This is a medication that is often given in Parkinson's disease along with levodopa in the form of carbidopa-levodopa, or Sinemet. This medication works the same way with levodopa in helping it get into the brain and improve the symptoms of PD. The only difference is that levodopa works like the chemical dopamine, whereas droxidopa works like norepinephrine. Up to this point, we have not had a way to correct the low norepinephrine levels in Parkinson's disease. Therefore, this study gives us the chance to investigate the effectiveness of a potential new treatment for PD patients.
The research will be conducted in a community in central Taiwan. Inclusion criteria are people over the age of 65 in the community. All participants will be randomly assigned to either the experimental group or the control group. The experimental group will receive the breathing training of abdominal diaphragmatic breathing method combined with incentive spiromete. The control group is only taught the breathing training of abdominal diaphragmatic breathing. Four assessment tools will be used, including the demographic questionnaire, respiratory capacity indicators, Modified Medical Research Council (mMRC) Dyspnea Scale, and the World Health Organization Quality of Life-BREF Taiwan Version (WHOQOL-BREF; WHOQOL-BREF). Data analysis will be performed by independent sample t test, paired t test, and repeated measures analysis. All data analysis will be performed by SPSS version 22.0.
Compositions discussed herein are useful for treating a patient infected with a coronavirus, notably SARS-CoV-2 or COVID-19. The compositions to be administered to an infected patient utilize inhibitors of SARS-CoV-2 papain-like protease (PL pro ). Several of these inhibitors include available hepatitis C virus (HCV) drugs that are already FDA-approved. These PL pro  inhibitors have been found to be strongly synergistic with inhibitors of SARS- CoV-2 polymerases, such as RNA-dependent RNA polymerase (RdRp). One such polymerase inhibitor, remdesivir, is already in use as an anti-viral treatment of patients with COVID-19. The PL pro  inhibitors, including repurposed HCV drugs such as grazoprevir, vaniprevir, and paritaprevir, increase remdesivir's ability to suppress coronavirus replication antiviral activity as much as 10-fold. These compositions can provide more effective patient therapies with less toxicity and side effects compared with the current standard of care, as well as enable outpatient treatment for COVID-19 with orally ingestible polymerase inhibitors such as molnupiravir (MK-4482/EIDD-2801).
BACKGROUND: The generation of new eggplant (Solanum melongena L.) cultivars with drought tolerance is a main challenge in the current context of climate change. In this study, the eight parents (seven of S. melongena and one of the wild relative S. incanum L.) of the first eggplant MAGIC (Multiparent Advanced Generation Intercrossing) population, together with four F1 hybrids amongst them, five S5 MAGIC recombinant inbred lines selected for their genetic diversity, and one commercial hybrid were evaluated in young plant stage under water stress conditions (30% field capacity; FC) and control conditions (100% FC). After a 21-day treatment period, growth and biomass traits, photosynthetic pigments, oxidative stress markers, antioxidant compounds, and proline content were evaluated.
RESULTS: Significant effects (p < 0.05) were observed for genotype, water treatments and their interaction in most of the traits analyzed. The eight MAGIC population parental genotypes displayed a wide variation in their responses to water stress, with some of them exhibiting enhanced root development and reduced foliar biomass. The commercial hybrid had greater aerial growth compared to root growth. The four F1 hybrids among MAGIC parents differed in their performance, with some having significant positive or negative heterosis in several traits. The subset of five MAGIC lines displayed a wide diversity in their response to water stress.
CONCLUSION: The results show that a large diversity for tolerance to drought is available among the eggplant MAGIC materials, which can contribute to developing drought-tolerant eggplant cultivars.
PROBLEM TO BE SOLVED: To obtain a new pearlescent pigment which can exhibit quite a novel color resulting from the compound action of the color of mica and the interference color by coating a reduced titanium-containing blue synthetic mica with a metal oxide. SOLUTION: The synthetic mica is prepared from e.g. fluorophlogopite by a fusion synthetic method such as the crucible method or the aging fusion method which are performed at 1,300-1,600 deg.C. The titanium content of the starting material for its production depends upon the aimed density of blue color and may be in the range of 1-15wt.%. The synthesis is carried out in a reducing atmosphere formed by injecting a reducing gas or a reducing agent such as carbon into the melt of the starting material. After the material is molten, the melt is crystallized to obtain a blue synthetic mica. If necessary, other coloring elements such as iron and cobalt are added to the system. Since the synthetic mica needs to have a smooth surface, large crystals obtained by crystallizing the melt in an insalating vessel are pulverized.  It is desirable that the obtained synthetic mica has a breadth and a length each of which is 3-100μm and a thickness of 0.05-1μm. The mica powder is coated with a metal oxide by firing by a known method.